Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- VITALIndependent statistical analysis of Friendship Bench Adaptation to Improve Mental Health & HIV Care Engagement Outcomes Among PLWH and PWID in Vietnam: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- VITALIndependent statistical analysis of The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors: primary endpoint results, effect estimate with confidence…
- VITALITY-ALSIndependent statistical analysis of Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- VitalpsIndependent statistical analysis of Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled LPS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART: Complete Statistical AnalysisIndependent statistical analysis of Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Vitamin D and Breast Cancer Biomarkers in Female Patients: Complete Statistical AnalysisIndependent statistical analysis of Vitamin D and Breast Cancer Biomarkers in Female Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01224678).
- Vitamin D Supplementation Reduces Renin-Angiotensin System Activity in Obesity: Complete Statistical AnalysisIndependent statistical analysis of Vitamin D Supplementation Reduces Renin-Angiotensin System Activity in Obesity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01068418).
- Vitamin D/Calcium Polyp Prevention Study: Complete Statistical AnalysisIndependent statistical analysis of Vitamin D/Calcium Polyp Prevention Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00153816).
- Vitamin K Supplementation in Post-Menopausal Osteopenia: Complete Statistical AnalysisIndependent statistical analysis of Vitamin K Supplementation in Post-Menopausal Osteopenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00150969).
- VitaminCIndependent statistical analysis of Study of High Dose Vitamin C On Outcome in Cardiac Surgery Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- VIV-FIHIndependent statistical analysis of EasyCrossTM Device-Self-centering Catheter: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06412354).
- VIVA-MINDIndependent statistical analysis of A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- VIVA-VAIndependent statistical analysis of Vitamin D in Vulnerable Adults (VIVA-VA): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01170273).
- ViVIDIndependent statistical analysis of Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- VIVID-1Independent statistical analysis of A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03926130).
- VMBIndependent statistical analysis of Rwanda Vaginal Microbiota Restoration Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02459665).
- vMBSRIndependent statistical analysis of Video Based Mindfulness Based Stress Reduction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02705586).
- vMetrics-AMSIndependent statistical analysis of Remote Home Prothrombin Time (PT)/International Normalized Ratio (INR) Monitoring and Patient Management System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- VMPIndependent statistical analysis of Meditation Interventions for Treatment of PTSD in Veterans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01548742).
- VNS-REHABIndependent statistical analysis of Pivotal Study of VNS During Rehab After Stroke (VNS-REHAB): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03131960).
- VOICEIndependent statistical analysis of VOICE: Values and Options in Cancer Care: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01485627).
- Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study: Complete Statistical AnalysisIndependent statistical analysis of Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study: primary endpoint results, effect estimate with…
- VOLVERIndependent statistical analysis of Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- VOR-IISRIndependent statistical analysis of Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02969876).
- Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Vorinostat in Treating Patients With Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Vorinostat in Treating Patients With Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00305773).
- Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00330161).
- Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme: Complete Statistical AnalysisIndependent statistical analysis of Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00238303).
- Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma: primary endpoint results, effect…
- Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction: Complete Statistical AnalysisIndependent statistical analysis of Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy: Complete Statistical AnalysisIndependent statistical analysis of Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- VOYAGER PADIndependent statistical analysis of Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower…
- VPAIndependent statistical analysis of Closure of Muscular Ventricular Septal Defects (VSDs) With the AMPLATZER Muscular VSD (MuVSD) Occluder - Post Approval Study: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- VPCIndependent statistical analysis of Co-Design and Pilot Testing of Peer-led Community Outreach to Improve Equity, Veteran-Centeredness and Uptake of Lung Cancer Screening: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- VR-DCSIndependent statistical analysis of Virtual Reality & D-cycloserine (DCS) for Posttraumatic Stress Disorder (PTSD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00632632).
- VR-IOMSIndependent statistical analysis of Virtual Reality-Base Intelligent Orientation and Mobility Specialists Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04639531).
- VR-THEIAIndependent statistical analysis of Impact of Virtual Reality on Pre-procedural anxieTy Prior to Heart cathEterIzAtion - VR-THEIA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- VRI01Independent statistical analysis of Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- VRPE ExtensionIndependent statistical analysis of Comparing Virtual Reality Exposure Therapy to Prolonged Exposure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01459705).
- VSLIndependent statistical analysis of Veteran Stress and Learning Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00674570).
- VX-950-C211 – A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection: Complete Statistical AnalysisIndependent statistical analysis of VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection: primary endpoint results,…
- Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan): Complete Statistical AnalysisIndependent statistical analysis of Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02146378).
- VyvanceIndependent statistical analysis of Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01486810).
- Vyxeos for Induction of Low- or Intermediate-risk.: Complete Statistical AnalysisIndependent statistical analysis of Vyxeos for Induction of Low- or Intermediate-risk.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05599360).
- W-SUDs for COVID-19: Complete Statistical AnalysisIndependent statistical analysis of W-SUDs for COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04460027).
- W8Loss2Go: mHealth Weight Management Strategy: Complete Statistical AnalysisIndependent statistical analysis of W8Loss2Go: mHealth Weight Management Strategy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02689154).
- Wait and SeeIndependent statistical analysis of Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Walking Aids in the Management of Hip Osteoarthritis: Complete Statistical AnalysisIndependent statistical analysis of Walking Aids in the Management of Hip Osteoarthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00506714).
- Walking Aids in the Management of Knee Osteoarthritis: Complete Statistical AnalysisIndependent statistical analysis of Walking Aids in the Management of Knee Osteoarthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00223795).
- Walking to School Supports: Complete Statistical AnalysisIndependent statistical analysis of Walking to School Supports: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04089020).